In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca ...

In internal medicines, we remain on track to provide an upgrade of our dose optimization studies of ... in U.S. vaccination rates at relatively low levels. Our assumptions for 2025 are on par ...

Within the legacy portfolio, higher sales of Eliquis were offset by the expected ... on the benefits of Opdivo Qvantig, and we expect low single-digit growth for this product and Opdivo taken ...

[44] The last dose of dabigatran was given 49 (35 ... and major bleeding was also reduced with apixaban compared to aspirin (5.3% vs 7.2% per year for intention-to-treat analysis, HR 0.74 ...

Anticoagulation (use of dabigatran, rivaroxaban, edoxaban, apixaban, heparin (therapeutic dose), warfarin) was included in the ... was not associated with reduced disability in adjusted logistic, or ...

Among patients with renal cell carcinoma (RCC), the Food and Drug Administration (FDA)-approved starting dose of 1.34 milligrams (mg) of Fotivda (tivozanib) resulted in greater antitumor activity than ...

found that rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to low-dose aspirin, but rates were higher for rivaroxaban. These findings can help patients with ...